SCYNEXIS Stock News

JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista

JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan

Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance. The company's approved product, ibrexafungerp, has been licensed to GSK with anticipated peak sal

We downgrade Scynexis to a sell rating following the voluntary recall of antifungal pill, Brexafemme. Historical precedence suggests that manufacturing recalls can take months to resolve, and for a si

SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.

As a rule of thumb, you should stay away from penny stocks. When you see shares priced near a buck (or even below), there's usually a reason for it – and not a good one.

JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan

SCYX's 1Q23 earnings highlights steadily underwhelming ibrexafungerp sales, with substantial growth expected in 2024/2025 once GSK begins promotion. Phase 3 MARIO trial data, pivotal for potential lab

Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens.

Scynexis (SCYX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.51 per share a year ago.

JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive

GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. GSK will pay SCYNEXIS $90 million upfront, with additional milestone pay

Use these tips to identify penny stocks opportunities The post Penny Stocks: Technical Approach to Finding Opportunities  appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto

Scynexis (NASDAQ: SCYX ) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. Brexafemme is an antifungal for the treatment of vulvovaginal candi